Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia.

The aim of the present study was to delineate the mechanism(s) responsible for the increased secretion of VLDL (very-low-density lipoprotein) particles in patients with FCH (familial combined hyperlipidaemia). In 194 young adults (<25 years of age) recruited from families with FCH, we investigated how plasma lipids, (apo)lipoproteins and BMI (body mass index) varied with age. Furthermore, we performed a 5-year follow-up study of clinical and biochemical characteristics of a subset of this population (n=85) stratified by apoB (apolipoprotein B) levels (below or above the 75th percentile adjusted for age and gender). Plasma apoB concentration (r=0.45, P<0.0001), triacylglycerol (triglyceride) concentration (r=0.45, P<0.0001), LDL (low-density lipoprotein) subfraction profile (r=-0.46, P<0.0001) and BMI (r=0.51, P<0.0001) were significantly associated with age. Plasma apoB concentration in the hyperapoB group was already elevated at a young age, whereas other characteristics of FCH, as observed in adults, including triacylglycerol levels >1.5 mmol/l and/or small-dense LDL, were observed only sporadically. After the 5-year follow-up, BMI increased in both groups, and this increase was associated with changes in apoB (r=0.27, P<0.05), triacylglycerol (r=0.30, P<0.01), VLDL cholesterol (r=0.22, P<0.05), VLDL triacylglycerol (r=0.25, P<0.05) and high-density lipoprotein cholesterol (r=-0.27, P<0.05). In conclusion, we have found indirect evidence of a primary, presumably genetically determined, increase in plasma apoB concentration occurring early in life of offspring from families with FCH. However, aging-related post-maturation increases in adipose tissue mass also appear to contribute to an aggravation and/or modulation of this genetically determined apoB overproduction.

[1]  S. Horswell,et al.  New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia Supported by the Medical Research Council and the British Heart Foundation. Published, JLR Papers in Press, November 20, 2008. , 2009, Journal of Lipid Research.

[2]  Antonio Gaddi,et al.  Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date , 2007, Vascular health and risk management.

[3]  S. Yusuf,et al.  Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study , 2005, The Lancet.

[4]  J. Hendriks,et al.  Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study , 2004, Circulation.

[5]  M. Noakes,et al.  Weight loss, diet composition and cardiovascular risk , 2004, Current opinion in lipidology.

[6]  J. Pankow,et al.  Coronary Artery Disease Risk in Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia: A Case-Control Comparison From the National Heart, Lung, and Blood Institute Family Heart Study , 2003, Circulation.

[7]  J. Pasman,et al.  Theophylline improves hypoglycemia unawareness in type 1 diabetes. , 2002, Diabetes.

[8]  J. Hendriks,et al.  Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[9]  P. Demacker,et al.  Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. , 2000, Atherosclerosis.

[10]  J. Kastelein,et al.  The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. , 2000, Atherosclerosis.

[11]  K. Cianflone,et al.  Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. , 2000, Atherosclerosis.

[12]  J. Graaf,et al.  Defects of lipoprotein metabolism in familial combined hyperlipidaemia. , 1998, Current opinion in lipidology.

[13]  M. Carroll,et al.  Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). , 1997, Clinical chemistry.

[14]  P. Demacker,et al.  Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low‐density lipoprotein heterogeneity , 1997, European journal of clinical investigation.

[15]  C. Tack,et al.  Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[16]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[17]  P. Demacker,et al.  Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. , 1996, Atherosclerosis.

[18]  G. Watts,et al.  Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects. , 1995, Metabolism: clinical and experimental.

[19]  P. Cullen,et al.  Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[20]  A. Dattilo,et al.  Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[21]  J. Cortner,et al.  Familial combined hyperlipidaemia: Use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver , 1991, Journal of Inherited Metabolic Disease.

[22]  K. Cianflone,et al.  Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. , 1990, Journal of lipid research.

[23]  J. Cortner,et al.  Prevalence and expression of familial combined hyperlipidemia in childhood. , 1990, The Journal of pediatrics.

[24]  A. Sniderman,et al.  Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. , 1986, The Journal of clinical investigation.

[25]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[26]  A. Kissebah,et al.  Low Density Lipoprotein Metabolism in Familial Combined Hyperlipidemia: Mechanism of the Multiple Lipoprotein Phenotypic Expression , 1984, Arteriosclerosis.

[27]  A. Kissebah,et al.  Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. , 1981, Metabolism: clinical and experimental.

[28]  P. Demacker,et al.  A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. , 1980, Clinical chemistry.

[29]  B. Lewis,et al.  Kinetic bases of the primar hperlipidaemias: studies of apolipoprotein B turnover in geneticall defined subjects , 1980 .

[30]  A. Chait,et al.  Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia , 1980, European journal of clinical investigation.

[31]  W. S. Handley.  Case of Recurrence in the Posterior Vaginal Wall Three Years after Abdomino-perineal Excision for Carcinoma Recti , 1919, Proceedings of the Royal Society of Medicine.

[32]  A. Sniderman,et al.  The adipocyte life cycle hypothesis. , 2006, Clinical science.

[33]  A. Stalenhoef,et al.  Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. , 2002, Journal of the Royal Society of Medicine.

[34]  C. Aguilar-Salinas,et al.  A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[35]  P. Wilson,et al.  Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. , 1996, Clinical chemistry.